Fatty Liver Drives Hyperglycemia Through Liver–Gut Signaling : Cell Metab | Jun 2026

Introduction:

Metabolic dysfunction–associated steatotic liver disease (MASLD) is closely linked to insulin resistance and type 2 diabetes, with the liver traditionally viewed as a key regulator of blood glucose through hepatic glucose production. However, emerging evidence suggests that metabolic communication between the liver and other organs may also play a critical role in glucose homeostasis.

Problem Statement:

While excessive hepatic gluconeogenesis is a well-established contributor to hyperglycemia, the mechanisms by which fatty liver influences distant metabolic tissues remain incompletely understood. Identifying novel liver-derived signals that disrupt glucose regulation could reveal new therapeutic targets for diabetes and metabolic liver disease.

Summary:

This study uncovers a previously unrecognized liver–gut communication pathway through which fatty liver promotes hyperglycemia. The investigators demonstrate that hepatocytes release alkaline phosphatase (ALP), which acts remotely on intestinal stem cells and alters their differentiation program. Mechanistically, ALP activates a signaling cascade involving α2δ-1, calcium channel translocation, and calcineurin–NFATC2 signaling, ultimately suppressing SOX21 expression. Reduced SOX21 activity lowers BMP7 production and impairs differentiation of intestinal stem cells into enteroendocrine L-cells. As a result, production of glucose-lowering gut hormones is diminished, contributing to worsening hyperglycemia. Importantly, this mechanism operates independently of increased hepatic glucose production, revealing an entirely new pathway linking fatty liver to systemic glucose dysregulation. Therapeutically, inhibition of hepatic ALP synthesis improved glycemic control and enhanced the glucose-lowering effects of metformin, suggesting potential clinical relevance. These findings redefine the role of the liver in metabolic regulation by demonstrating that fatty liver can directly influence intestinal stem cell fate and endocrine function through endocrine-like signalling. Beyond advancing understanding of MASLD-associated diabetes, the study identifies the ALP–SOX21 axis as a promising therapeutic target. Overall, this work provides compelling evidence that liver–gut communication is a fundamental regulator of blood glucose homeostasis and opens new avenues for treating metabolic disease by targeting inter-organ signalling pathways rather than hepatic metabolism alone.